nodes	percent_of_prediction	percent_of_DWPC	metapath
Droxidopa—SLC6A2—autonomic nervous system—Gilles de la Tourette syndrome	0.0355	0.158	CbGeAlD
Droxidopa—PAH—nervous system—Gilles de la Tourette syndrome	0.0165	0.0738	CbGeAlD
Droxidopa—PAH—central nervous system—Gilles de la Tourette syndrome	0.0159	0.071	CbGeAlD
Droxidopa—PAH—brain—Gilles de la Tourette syndrome	0.0126	0.0564	CbGeAlD
Droxidopa—DDC—midbrain—Gilles de la Tourette syndrome	0.0115	0.0512	CbGeAlD
Droxidopa—DDC—nervous system—Gilles de la Tourette syndrome	0.00943	0.0421	CbGeAlD
Droxidopa—DDC—central nervous system—Gilles de la Tourette syndrome	0.00908	0.0405	CbGeAlD
Droxidopa—ADRA1B—nervous system—Gilles de la Tourette syndrome	0.00743	0.0332	CbGeAlD
Droxidopa—ADRA1D—nervous system—Gilles de la Tourette syndrome	0.00727	0.0324	CbGeAlD
Droxidopa—DDC—brain—Gilles de la Tourette syndrome	0.00721	0.0322	CbGeAlD
Droxidopa—ADRA1B—central nervous system—Gilles de la Tourette syndrome	0.00716	0.0319	CbGeAlD
Droxidopa—ADRA1D—central nervous system—Gilles de la Tourette syndrome	0.007	0.0312	CbGeAlD
Droxidopa—ADRA1B—brain—Gilles de la Tourette syndrome	0.00568	0.0253	CbGeAlD
Droxidopa—ADRA1D—brain—Gilles de la Tourette syndrome	0.00556	0.0248	CbGeAlD
Droxidopa—L-DOPA—DRD4—Gilles de la Tourette syndrome	0.00554	0.164	CrCbGaD
Droxidopa—ADRB1—nervous system—Gilles de la Tourette syndrome	0.00528	0.0236	CbGeAlD
Droxidopa—Dopamine—DRD4—Gilles de la Tourette syndrome	0.00515	0.153	CrCbGaD
Droxidopa—ADRB1—central nervous system—Gilles de la Tourette syndrome	0.00509	0.0227	CbGeAlD
Droxidopa—ADRA2C—midbrain—Gilles de la Tourette syndrome	0.00484	0.0216	CbGeAlD
Droxidopa—L-DOPA—DRD3—Gilles de la Tourette syndrome	0.00478	0.142	CrCbGaD
Droxidopa—SLC6A2—nervous system—Gilles de la Tourette syndrome	0.00449	0.02	CbGeAlD
Droxidopa—Dopamine—DRD3—Gilles de la Tourette syndrome	0.00444	0.132	CrCbGaD
Droxidopa—SLC6A2—central nervous system—Gilles de la Tourette syndrome	0.00433	0.0193	CbGeAlD
Droxidopa—ADRA1A—nervous system—Gilles de la Tourette syndrome	0.00418	0.0186	CbGeAlD
Droxidopa—Dopamine—SLC6A3—Gilles de la Tourette syndrome	0.00413	0.123	CrCbGaD
Droxidopa—ADRB1—brain—Gilles de la Tourette syndrome	0.00404	0.018	CbGeAlD
Droxidopa—ADRA1A—central nervous system—Gilles de la Tourette syndrome	0.00402	0.0179	CbGeAlD
Droxidopa—ADRA2C—nervous system—Gilles de la Tourette syndrome	0.00398	0.0178	CbGeAlD
Droxidopa—ADRA2A—midbrain—Gilles de la Tourette syndrome	0.00386	0.0172	CbGeAlD
Droxidopa—ADRA2C—central nervous system—Gilles de la Tourette syndrome	0.00383	0.0171	CbGeAlD
Droxidopa—SLC6A2—brain—Gilles de la Tourette syndrome	0.00343	0.0153	CbGeAlD
Droxidopa—L-DOPA—DRD2—Gilles de la Tourette syndrome	0.0033	0.098	CrCbGaD
Droxidopa—Norepinephrine—DRD2—Gilles de la Tourette syndrome	0.0033	0.098	CrCbGaD
Droxidopa—ADRA1A—brain—Gilles de la Tourette syndrome	0.00319	0.0142	CbGeAlD
Droxidopa—ADRA2A—nervous system—Gilles de la Tourette syndrome	0.00318	0.0142	CbGeAlD
Droxidopa—Dopamine—DRD2—Gilles de la Tourette syndrome	0.00307	0.0911	CrCbGaD
Droxidopa—ADRA2A—central nervous system—Gilles de la Tourette syndrome	0.00306	0.0136	CbGeAlD
Droxidopa—ADRA2C—brain—Gilles de la Tourette syndrome	0.00304	0.0136	CbGeAlD
Droxidopa—ADRA2A—brain—Gilles de la Tourette syndrome	0.00243	0.0108	CbGeAlD
Droxidopa—ADRA1D—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00237	0.00319	CbGpPWpGaD
Droxidopa—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.00229	0.00309	CbGpPWpGaD
Droxidopa—DDC—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.00227	0.00306	CbGpPWpGaD
Droxidopa—ADRB2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00217	0.00293	CbGpPWpGaD
Droxidopa—ADRA1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00215	0.0029	CbGpPWpGaD
Droxidopa—ADRB2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00211	0.00284	CbGpPWpGaD
Droxidopa—ADRA2A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.002	0.0027	CbGpPWpGaD
Droxidopa—PAH—Metabolism—HDC—Gilles de la Tourette syndrome	0.00199	0.00268	CbGpPWpGaD
Droxidopa—DDC—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00195	0.00262	CbGpPWpGaD
Droxidopa—SLC16A10—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.00175	0.00235	CbGpPWpGaD
Droxidopa—SLC6A2—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.00165	0.00223	CbGpPWpGaD
Droxidopa—ADRB3—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00163	0.00219	CbGpPWpGaD
Droxidopa—ADRB3—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00158	0.00213	CbGpPWpGaD
Droxidopa—ADRA1D—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00154	0.00208	CbGpPWpGaD
Droxidopa—ADRB3—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00147	0.00198	CbGpPWpGaD
Droxidopa—ADRB3—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00139	0.00188	CbGpPWpGaD
Droxidopa—ADRB2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00138	0.00185	CbGpPWpGaD
Droxidopa—ADRB3—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00135	0.00182	CbGpPWpGaD
Droxidopa—DDC—Metabolism—HDC—Gilles de la Tourette syndrome	0.00129	0.00173	CbGpPWpGaD
Droxidopa—ADRB3—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00126	0.0017	CbGpPWpGaD
Droxidopa—ADRB3—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00106	0.00143	CbGpPWpGaD
Droxidopa—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00106	0.00143	CbGpPWpGaD
Droxidopa—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.00104	0.0014	CbGpPWpGaD
Droxidopa—ADRA2B—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00103	0.00139	CbGpPWpGaD
Droxidopa—ADRB3—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00103	0.00139	CbGpPWpGaD
Droxidopa—ADRB3—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00103	0.00139	CbGpPWpGaD
Droxidopa—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00103	0.00139	CbGpPWpGaD
Droxidopa—ADRA2B—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.001	0.00135	CbGpPWpGaD
Droxidopa—ADRB1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000965	0.0013	CbGpPWpGaD
Droxidopa—ADRA2C—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.000962	0.0013	CbGpPWpGaD
Droxidopa—ADRB3—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000959	0.00129	CbGpPWpGaD
Droxidopa—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000958	0.00129	CbGpPWpGaD
Droxidopa—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000956	0.00129	CbGpPWpGaD
Droxidopa—ADRB2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000944	0.00127	CbGpPWpGaD
Droxidopa—ADRB1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000937	0.00126	CbGpPWpGaD
Droxidopa—ADRA2C—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000934	0.00126	CbGpPWpGaD
Droxidopa—ADRA2B—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000932	0.00126	CbGpPWpGaD
Droxidopa—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000928	0.00125	CbGpPWpGaD
Droxidopa—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000916	0.00123	CbGpPWpGaD
Droxidopa—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000907	0.00122	CbGpPWpGaD
Droxidopa—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000893	0.0012	CbGpPWpGaD
Droxidopa—SLC16A10—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000888	0.0012	CbGpPWpGaD
Droxidopa—ADRB3—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000882	0.00119	CbGpPWpGaD
Droxidopa—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000881	0.00119	CbGpPWpGaD
Droxidopa—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000879	0.00118	CbGpPWpGaD
Droxidopa—ADRB1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000873	0.00118	CbGpPWpGaD
Droxidopa—ADRA2C—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00087	0.00117	CbGpPWpGaD
Droxidopa—ADRA1D—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000868	0.00117	CbGpPWpGaD
Droxidopa—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000867	0.00117	CbGpPWpGaD
Droxidopa—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000865	0.00117	CbGpPWpGaD
Droxidopa—ADRB2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000854	0.00115	CbGpPWpGaD
Droxidopa—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000853	0.00115	CbGpPWpGaD
Droxidopa—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000827	0.00111	CbGpPWpGaD
Droxidopa—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00082	0.00111	CbGpPWpGaD
Droxidopa—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000819	0.0011	CbGpPWpGaD
Droxidopa—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000809	0.00109	CbGpPWpGaD
Droxidopa—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000808	0.00109	CbGpPWpGaD
Droxidopa—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000803	0.00108	CbGpPWpGaD
Droxidopa—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000795	0.00107	CbGpPWpGaD
Droxidopa—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000795	0.00107	CbGpPWpGaD
Droxidopa—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000785	0.00106	CbGpPWpGaD
Droxidopa—ADRA2A—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.000782	0.00105	CbGpPWpGaD
Droxidopa—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000781	0.00105	CbGpPWpGaD
Droxidopa—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000776	0.00105	CbGpPWpGaD
Droxidopa—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000765	0.00103	CbGpPWpGaD
Droxidopa—ADRA2A—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000759	0.00102	CbGpPWpGaD
Droxidopa—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000758	0.00102	CbGpPWpGaD
Droxidopa—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000753	0.00101	CbGpPWpGaD
Droxidopa—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000748	0.00101	CbGpPWpGaD
Droxidopa—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000743	0.001	CbGpPWpGaD
Droxidopa—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000741	0.000998	CbGpPWpGaD
Droxidopa—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000731	0.000985	CbGpPWpGaD
Droxidopa—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000731	0.000985	CbGpPWpGaD
Droxidopa—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000725	0.000977	CbGpPWpGaD
Droxidopa—ADRA1B—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00072	0.00097	CbGpPWpGaD
Droxidopa—ADRA2A—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000707	0.000952	CbGpPWpGaD
Droxidopa—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000706	0.000951	CbGpPWpGaD
Droxidopa—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000704	0.000949	CbGpPWpGaD
Droxidopa—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000692	0.000932	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000691	0.000931	CbGpPWpGaD
Droxidopa—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000681	0.000918	CbGpPWpGaD
Droxidopa—ADRB3—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000672	0.000905	CbGpPWpGaD
Droxidopa—ADRA1D—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000671	0.000904	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000671	0.000904	CbGpPWpGaD
Droxidopa—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000669	0.000901	CbGpPWpGaD
Droxidopa—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000656	0.000884	CbGpPWpGaD
Droxidopa—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000649	0.000875	CbGpPWpGaD
Droxidopa—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000644	0.000868	CbGpPWpGaD
Droxidopa—ADRA1A—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00064	0.000862	CbGpPWpGaD
Droxidopa—ADRB1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000629	0.000848	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000625	0.000842	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000624	0.00084	CbGpPWpGaD
Droxidopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000621	0.000837	CbGpPWpGaD
Droxidopa—ADRB2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000616	0.00083	CbGpPWpGaD
Droxidopa—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000611	0.000823	CbGpPWpGaD
Droxidopa—ADRB1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000611	0.000823	CbGpPWpGaD
Droxidopa—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000606	0.000816	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000606	0.000816	CbGpPWpGaD
Droxidopa—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000605	0.000815	CbGpPWpGaD
Droxidopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000603	0.000813	CbGpPWpGaD
Droxidopa—ADRB3—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000599	0.000808	CbGpPWpGaD
Droxidopa—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000598	0.000806	CbGpPWpGaD
Droxidopa—ADRB2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000598	0.000806	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000583	0.000785	CbGpPWpGaD
Droxidopa—ADRB3—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000582	0.000784	CbGpPWpGaD
Droxidopa—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000575	0.000774	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000573	0.000773	CbGpPWpGaD
Droxidopa—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000572	0.000771	CbGpPWpGaD
Droxidopa—ADRB1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000569	0.000767	CbGpPWpGaD
Droxidopa—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000566	0.000762	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000566	0.000762	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000564	0.00076	CbGpPWpGaD
Droxidopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000562	0.000757	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—HDC—Gilles de la Tourette syndrome	0.000559	0.000753	CbGpPWpGaD
Droxidopa—ADRB2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000557	0.00075	CbGpPWpGaD
Droxidopa—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000557	0.00075	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000557	0.00075	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000544	0.000733	CbGpPWpGaD
Droxidopa—ADRB3—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000542	0.00073	CbGpPWpGaD
Droxidopa—SLC6A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000529	0.000713	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000528	0.000712	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000527	0.00071	CbGpPWpGaD
Droxidopa—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000524	0.000706	CbGpPWpGaD
Droxidopa—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000519	0.000699	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000519	0.000699	CbGpPWpGaD
Droxidopa—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000512	0.00069	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000509	0.000686	CbGpPWpGaD
Droxidopa—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000494	0.000666	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000494	0.000666	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000492	0.000663	CbGpPWpGaD
Droxidopa—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000485	0.000653	CbGpPWpGaD
Droxidopa—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000477	0.000643	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000473	0.000638	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000461	0.000621	CbGpPWpGaD
Droxidopa—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000459	0.000619	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000459	0.000619	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—HDC—Gilles de la Tourette syndrome	0.000454	0.000611	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000438	0.00059	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000428	0.000577	CbGpPWpGaD
Droxidopa—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000424	0.000571	CbGpPWpGaD
Droxidopa—ADRB1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000399	0.000537	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000395	0.000532	CbGpPWpGaD
Droxidopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000394	0.00053	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00039	0.000526	CbGpPWpGaD
Droxidopa—ADRB2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00039	0.000526	CbGpPWpGaD
Droxidopa—ADRB3—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00038	0.000512	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000379	0.000511	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000369	0.000497	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000363	0.000489	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000356	0.000479	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000355	0.000478	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000353	0.000476	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000352	0.000475	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000348	0.000469	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000345	0.000465	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000345	0.000465	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000344	0.000464	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000342	0.000461	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000338	0.000455	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000329	0.000444	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000324	0.000437	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000323	0.000435	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000323	0.000435	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000322	0.000434	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000322	0.000433	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000321	0.000432	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00032	0.000431	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00032	0.000431	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000319	0.00043	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000316	0.000426	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000315	0.000424	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000315	0.000424	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000314	0.000423	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000312	0.000421	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000311	0.000419	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000307	0.000413	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.0003	0.000404	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000299	0.000403	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000298	0.000401	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000294	0.000397	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000293	0.000395	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000292	0.000394	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000291	0.000392	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00029	0.000391	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000289	0.00039	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000288	0.000388	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000286	0.000385	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000286	0.000385	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000279	0.000377	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00027	0.000364	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000267	0.00036	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000266	0.000359	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000261	0.000352	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00026	0.000351	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00026	0.00035	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000254	0.000342	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000247	0.000333	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000243	0.000327	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000242	0.000326	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000236	0.000319	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000236	0.000318	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000225	0.000304	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000225	0.000303	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000223	0.000301	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00022	0.000297	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00022	0.000296	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000209	0.000282	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000209	0.000281	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000205	0.000277	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000205	0.000276	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000204	0.000274	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000203	0.000274	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000203	0.000273	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.0002	0.00027	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000191	0.000257	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000189	0.000255	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000189	0.000255	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000189	0.000255	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000187	0.000252	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000186	0.000251	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000185	0.00025	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000184	0.000247	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000182	0.000246	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000181	0.000244	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000177	0.000238	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000174	0.000234	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000173	0.000233	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000171	0.000231	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000171	0.00023	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000169	0.000228	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000169	0.000227	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000169	0.000227	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000166	0.000223	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00016	0.000215	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000157	0.000212	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000154	0.000208	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000154	0.000207	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00015	0.000202	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000143	0.000193	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00014	0.000188	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000139	0.000188	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000133	0.000179	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00013	0.000175	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000121	0.000163	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00012	0.000161	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000118	0.000159	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000112	0.000151	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00011	0.000148	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	9.78e-05	0.000132	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	9.09e-05	0.000122	CbGpPWpGaD
